While pCR is strongly prognostic in triple-negative breast cancer (TNBC) and HER2+ disease, its prognostic value in ER+/HER2- disease is limited since such patients rarely respond with a pCR. The gene discussed is ERBB2; the disease is triple-negative breast carcinoma.